Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Keros Therapeutics Inc before investing.

In this article, we go over a few key elements for understanding Keros Therapeutics Inc’s stock price such as:

• Keros Therapeutics Inc’s current stock price and volume
• Why Keros Therapeutics Inc’s stock price changed recently
• Upgrades and downgrades for KROS from analysts
• KROS’s stock price momentum as measured by its relative strength

About Keros Therapeutics Inc (KROS)

Before we jump into Keros Therapeutics Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Want to learn more about Keros Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Keros Therapeutics Inc.

What Caused Keros Therapeutics Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 28, 2024, there were 2 analysts who downgraded Keros Therapeutics Inc’s stock and 5 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Keros Therapeutics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Keros Therapeutics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Keros Therapeutics Inc (KROS) by visiting AAII Stock Evaluator.

Relative Price Strength of Keros Therapeutics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 28, 2024, Keros Therapeutics Inc has a weighted four-quarter relative price strength of -4.70%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how Keros Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Keros Therapeutics Inc Stock Price: Bottom Line

As of July 1, 2024, Keros Therapeutics Inc’s stock price is $43.77, which is down 4.22% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Keros Therapeutics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.